General Disclaimers
Platform Role
AgeRejuvenation DBA Peptide Stacks is a managed services organization (MSO) that provides clinical infrastructure and care coordination services. AgeRejuvenation DBA Peptide Stacks does not practice medicine, provide medical advice, or dispense medications. All prescribing decisions are made exclusively by independent, licensed healthcare providers operating through affiliated professional medical entities in the states where they are licensed to practice.
Prescription Medications
Prescription medications are only available following a completed telehealth consultation and a clinical determination of appropriateness by a licensed provider. Whether to prescribe, and what to prescribe, is entirely within the provider's independent clinical judgment and subject to applicable laws and regulations.
Compounded Medications
Some treatments available through affiliated providers may involve compounded medications prepared by licensed, USA-based compounding pharmacies. Compounded medications may be appropriate when commercially available alternatives do not meet a patient's clinical needs.
Important: Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. They are not FDA-approved drug products. Your provider will discuss the risks and benefits of compounded medications with you during your consultation.
GLP-1 Weight Management — Compounded Semaglutide
Compounded semaglutide is not an FDA-approved drug product. FDA shortage status for branded semaglutide may affect the availability of compounded versions. Your provider will advise you on current availability.
BLACK BOX WARNING
Semaglutide and other GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In animal studies, GLP-1 receptor agonists caused thyroid C-cell tumors. The relevance to humans is unknown.
Seek Immediate Medical Attention For
- Severe nausea, vomiting, or diarrhea resulting in dehydration or inability to keep fluids down.
- Signs of kidney problems: decreased urination or swelling in the legs.
- Thyroid tumor symptoms: neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath.
- Pancreatitis: persistent, severe abdominal or back pain, with or without vomiting.
- Gallbladder disease: upper abdominal pain, fever, jaundice, or nausea.
- Liver problems: jaundice, elevated liver enzymes, or hepatitis signs.
- Diabetic retinopathy progression: new or worsening vision changes.
- Low blood sugar signs: dizziness, weakness, shakiness, headache, sweating, confusion, or rapid heartbeat.
- Worsening depression, behavioral changes, or thoughts of self-harm or suicide.
Drug Interactions
Semaglutide may interact with insulin, oral diabetes medications (especially sulfonylureas), and other glucose-lowering therapies, increasing the risk of hypoglycemia. It may also affect the absorption rate of oral medications due to effects on gastric emptying. Inform your provider of all medications, supplements, and herbal products you are taking.
Use in Special Populations
Do not use during pregnancy or while breastfeeding. Use effective contraception during treatment. Safety and efficacy have not been established in pediatric patients.
Do not share this medication with anyone else.
GLP-1 Weight Management — Compounded Tirzepatide
Compounded tirzepatide is not an FDA-approved drug product. FDA shortage status for branded tirzepatide may affect the availability of compounded versions.
WARNING — THYROID TUMOR RISK
Tirzepatide has been associated with thyroid C-cell tumors in animal studies. Do not use if you or any first-degree family member has a history of medullary thyroid carcinoma or MEN 2.
Serious Side Effects — Seek Medical Attention For
- Persistent or severe abdominal discomfort (possible pancreatitis).
- Signs of kidney problems from dehydration secondary to gastrointestinal symptoms.
- Gallbladder disease: upper abdominal pain, jaundice, fever, or stool color changes.
- Allergic reactions: facial swelling, hives, difficulty breathing, or rapid heartbeat.
- Hypoglycemia: dizziness, sweating, confusion, shakiness, or rapid heartbeat.
- New or worsening visual changes.
- Mood changes, depression, or thoughts of self-harm.
Common Side Effects
Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, belching, hair loss, and heartburn.
Drug Interactions
Increased hypoglycemia risk when combined with insulin or sulfonylureas. May reduce the effectiveness of oral contraceptives — discuss alternative contraception with your provider.
Use in Special Populations
Do not use during pregnancy or while breastfeeding. Use effective contraception during treatment.
NAD+ (Nicotinamide Adenine Dinucleotide)
NAD+ infusions and injections are not FDA-approved drug products for any indication. The statements in this section have not been evaluated by the FDA.
NAD+ is a coenzyme involved in cellular energy metabolism. It is used off-label in longevity, anti-aging, and neurological support protocols. NAD+ therapy may be administered via intravenous infusion, intramuscular injection, or subcutaneous injection depending on the clinical protocol.
Common Side Effects (Particularly with IV Administration)
- Flushing, warmth, and redness during infusion.
- Nausea, stomach cramping, or discomfort during infusion.
- Chest tightness or pressure (typically transient and resolves with slower infusion rate).
- Muscle cramping during infusion.
- Fatigue or light-headedness following infusion.
- Injection site reactions for non-IV routes.
Contraindications and Precautions
Use with caution in patients with a history of cancer, autoimmune conditions, or significant cardiovascular or hepatic disease. The safety of NAD+ therapy during pregnancy and breastfeeding has not been established. Inform your provider of all medications you are taking.
Drug Interactions
Potential interactions with certain medications affecting cellular metabolism exist but are not well-characterized. Disclose all medications, supplements, and herbal products to your provider before starting NAD+ therapy.
GLP-1 Compounded Medication — FDA Regulatory Disclosure
By initiating treatment with a compounded GLP-1 medication, you acknowledge that:
- Compounded semaglutide and tirzepatide are not FDA-approved drug products.
- The availability of your compounded medication may change at any time based on FDA shortage status determinations.
- If your compounded treatment becomes unavailable, your provider may recommend an alternative, including branded medications or a different treatment approach.
- Any transition in your treatment will be managed by your provider based on your individual clinical needs.
- AgeRejuvenation DBA Peptide Stacks cannot guarantee the continuous availability of any compounded GLP-1 medication.
Adverse Event Reporting and Contact Information
To report a suspected adverse reaction to any medication, contact:
- The FDA MedWatch program at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Your prescribing provider directly through the patient portal.
- Your dispensing pharmacy.
AgeRejuvenation DBA Peptide Stacks — Patient Support
Email: Support@peptidestacks.com
Phone: 855-ESTACKS (855-378-2257)
Disclaimer
This document is provided for informational purposes only. It does not constitute medical advice and is not a substitute for consultation with a licensed healthcare provider. AgeRejuvenation DBA Peptide Stacks, as a managed services organization, does not provide medical advice. All clinical decisions are made by independent, licensed healthcare providers. The statements in this document have not been independently reviewed or approved by the FDA unless otherwise noted.